<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="14151">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00328783</url>
  </required_header>
  <id_info>
    <org_study_id>02U.282</org_study_id>
    <secondary_id>2002-31</secondary_id>
    <nct_id>NCT00328783</nct_id>
  </id_info>
  <brief_title>Using the Active Breathing Control Device to Reduce Radiation Side Effects to Critical Structures in Breast Cancer</brief_title>
  <official_title>A Pilot Study Investigating Active Breathing Coordinator (ABC) to Reduce Radiation Dose to Normal Structures in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thomas Jefferson University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Thomas Jefferson University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the use of a device that helps coordinate the
      breathing cycle in the radiation treatment of the breast in order to minimize the radiation
      dose to the normal structures around the breast.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Active Breathing Coordinator (ABC) allows for temporary and reproducible immobilization
      of internal thoracic structures by monitoring the patient's breathing cycle and implementing
      a breath hold at a predefined lung volume level. While ABC is FDA approved and commercially
      available, only preliminary dosimetric data is available on a small number of patients with
      breast cancer. There is some data using ABC for intrathoracic malignancies, which shows that
      it is feasible and safe to use. ABC can be used to optimize the distance between chest wall,
      heart and liver. This allows adequate treatment of the breast and underlying chest wall
      while minimizing irradiated cardiac and liver volume.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2002</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care</study_design>
  <primary_outcome>
    <measure>Dosimetric Evaluation Magnitude of Reduction in Irradiated Normal Tissues</measure>
    <time_frame>At time of radiation</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate the magnitude of reduction in irradiated normal tissues (heart and lung) when using the Active Breathing Coordinator (ABC) in breast patients, as compared to standard, free-breathing.
The generated dose distributions from the free-breathing vs. ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms. Specifically, for the heart, the volume receiving 55 and 40 Gy will be evaluated; for the liver the volume receiving 50 and 36 Gy, and for the lung, the volume receiving 20 Gy. For the contralateral breast the volume receiving 20 Gy, 30 Gy and 50 Gy will be evaluated. Patients will be treated with the ABC device if there is at least 5 % relative reduction in the volume of a normal tissue irradiated to prescription dose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Patients With Reduction in Radiation</measure>
    <time_frame>30 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity Evaluation</measure>
    <time_frame>30 days post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate toxicity of ABC in breast cancer patients receiving adjuvant breast radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in Normal Tissue Irradiation</measure>
    <time_frame>30 days post-treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>To evaluate whether potential improvement in normal tissue irradiation can be predicted from standard simulation films, without subjecting patients to free-breathing plus controlled breathingCT scans</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity Monitoring</measure>
    <time_frame>30 days post-treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To monitor the toxicity of treatment of adjuvant radiotherapy for breast cancer with the ABC device.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">112</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Active Breathing Coordinator</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients breathe through the ABC device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Active Breathing Coordinator (ABC)</intervention_name>
    <description>The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.</description>
    <arm_group_label>Active Breathing Coordinator</arm_group_label>
    <other_name>ABC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <arm_group_label>Active Breathing Coordinator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Requiring adjuvant or post mastectomy radiation therapy with tangential fields or
             3-fields

          -  Adequate pulmonary function

          -  Presence of 5 cc of the heart or liver with the simulation fields

          -  Karnofsky Performance Status (KPS) equal to or greater than 70

        Exclusion Criteria:

          -  Pregnant women

          -  Patients who have had previous ipsilateral breast or thoracic radiation therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pramila Rani Anne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Thomas Jefferson University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.KimmelCancerCenter.org</url>
    <description>Kimmel Cancer Center at Thomas Jefferson University, an NCI-Designated Cancer Center</description>
  </link>
  <link>
    <url>http://www.JeffersonHospital.org</url>
    <description>Thomas Jefferson University Hospitals</description>
  </link>
  <verification_date>January 2015</verification_date>
  <lastchanged_date>January 14, 2015</lastchanged_date>
  <firstreceived_date>May 19, 2006</firstreceived_date>
  <firstreceived_results_date>January 27, 2014</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast cancer</keyword>
  <keyword>Active Breathing Control</keyword>
  <keyword>Active Breathing Coordinator</keyword>
  <keyword>ABC</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Active Breathing Coordinator</title>
          <description>Patients breathe through the ABC device
Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Could not tolerate ABC</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No heart in RT field</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Active Breathing Coordinator</title>
          <description>Patients breathe through the ABC device
Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="112"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="97"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="15"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54.19" spread="10.82"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="112"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="112"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Dosimetric Evaluation Magnitude of Reduction in Irradiated Normal Tissues</title>
        <description>To evaluate the magnitude of reduction in irradiated normal tissues (heart and lung) when using the Active Breathing Coordinator (ABC) in breast patients, as compared to standard, free-breathing.
The generated dose distributions from the free-breathing vs. ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms. Specifically, for the heart, the volume receiving 55 and 40 Gy will be evaluated; for the liver the volume receiving 50 and 36 Gy, and for the lung, the volume receiving 20 Gy. For the contralateral breast the volume receiving 20 Gy, 30 Gy and 50 Gy will be evaluated. Patients will be treated with the ABC device if there is at least 5 % relative reduction in the volume of a normal tissue irradiated to prescription dose.</description>
        <time_frame>At time of radiation</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Active Breathing Coordinator</title>
            <description>Patients breathe through the ABC device
Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="86"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Dosimetric Evaluation Magnitude of Reduction in Irradiated Normal Tissues</title>
            <description>To evaluate the magnitude of reduction in irradiated normal tissues (heart and lung) when using the Active Breathing Coordinator (ABC) in breast patients, as compared to standard, free-breathing.
The generated dose distributions from the free-breathing vs. ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms. Specifically, for the heart, the volume receiving 55 and 40 Gy will be evaluated; for the liver the volume receiving 50 and 36 Gy, and for the lung, the volume receiving 20 Gy. For the contralateral breast the volume receiving 20 Gy, 30 Gy and 50 Gy will be evaluated. Patients will be treated with the ABC device if there is at least 5 % relative reduction in the volume of a normal tissue irradiated to prescription dose.</description>
            <units>Gy</units>
            <param>Mean</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>Free breathing (heart)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="3.0" lower_limit="2.6" upper_limit="3.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ABC (heart)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="1.1" lower_limit="0.9" upper_limit="1.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Free breathing (lung)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="6.0" lower_limit="5.3" upper_limit="6.8"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>ABC (lung)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="5.4" lower_limit="4.9" upper_limit="5.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Evaluation</title>
        <description>To evaluate toxicity of ABC in breast cancer patients receiving adjuvant breast radiotherapy</description>
        <time_frame>30 days post-treatment</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Improvement in Normal Tissue Irradiation</title>
        <description>To evaluate whether potential improvement in normal tissue irradiation can be predicted from standard simulation films, without subjecting patients to free-breathing plus controlled breathingCT scans</description>
        <time_frame>30 days post-treatment</time_frame>
        <safety_issue>No</safety_issue>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Toxicity Monitoring</title>
        <description>To monitor the toxicity of treatment of adjuvant radiotherapy for breast cancer with the ABC device.</description>
        <time_frame>30 days post-treatment</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients With Reduction in Radiation</title>
        <time_frame>30 days</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Active Breathing Coordinator</title>
            <description>Patients breathe through the ABC device
Active Breathing Coordinator (ABC): The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="86"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Proportion of Patients With Reduction in Radiation</title>
            <units>proportion of patients</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <sub_title>5% reduction (heart)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.94" lower_limit="0.86" upper_limit="0.98"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>20% reduction (heart)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.88" lower_limit="0.78" upper_limit="0.95"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>5% reduction (lung)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.56" lower_limit="0.41" upper_limit="0.70"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>20% reduction (lung)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.35" lower_limit="0.22" upper_limit="0.49"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Serious Adverse Events and Other Adverse Events were not collected/assessed.</desc>
      <group_list>
        <group group_id="E1">
          <title>Active Breathing Coordinator</title>
          <description>Patients breathe through the ABC device
Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Rani Anne, MD</name_or_title>
      <organization>Thomas Jefferson University</organization>
      <phone>215-955-6045</phone>
      <email>Rani.Anne@jeffersonhospital.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
